Skip to main content
S

Sunho Biologics, Inc. — Investor Relations & Filings

Ticker · 2898 HKEX Manufacturing
Open in API
Filings indexed 74 across all filing types
Latest filing 2026-01-02 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2898

About Sunho Biologics, Inc.

http://www.sunho-bio.com.cn

Sunho Biologics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class/best-in-class biologics. The company specializes in modulating the immune microenvironment by directly regulating the innate and adaptive immune systems, with a primary therapeutic focus on oncology and autoimmune diseases. Sunho develops various immunotherapies, including antibody-cytokines (immunocytokines). Its core competitive advantage is built upon three proprietary technology platforms: the AIC™ platform for scalable antibody-cytokine fusion protein development; the AEA™ platform, a FUT8 knockout cell line designed to enhance antibody-dependent cell-mediated cytotoxicity (ADCC); and the AIM™ platform, which focuses on developing bispecific/multispecific antibodies based on innate immune stimulation. The company maintains a pipeline of 9 innovative candidates, with 6 currently in clinical development.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report movements in their securities, share capital, and treasury shares on a monthly basis. Since it details changes in share capital and issued shares, it falls under the category of share capital changes and regulatory reporting. Given the specific nature of the HKEX monthly return, it is best classified as a Regulatory Filing (RNS).
2026-01-02 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report movements in their securities, share capital, and treasury shares on a monthly basis. While it involves share capital, it is a recurring regulatory filing rather than a specific 'Share Issue/Capital Change' (SHA) announcement for a single event, and it is not a report publication announcement. Given the specific nature of the HKEX monthly return, it falls under the 'Regulatory Filings' category.
2025-12-02 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2025
Share Issue/Capital Change Classification · 1% confidence The document is the FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under HKEX Chapter 19B, detailing movements in authorised/registered share capital and issued shares. It is not an earnings release, annual report, or management announcement but a regulatory submission reporting share capital and issuance movements. This aligns with the “Share Issue/Capital Change” category (SHA).
2025-11-03 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2025
Regulatory Filings Classification · 1% confidence The document is a standard monthly return (Form FF301) filed with the Hong Kong Exchange detailing movements in share capital and issued shares for the month. It is a recurring regulatory submission rather than an annual report, earnings release, or specific share issuance announcement. It does not announce a one‐off capital change (e.g., new issue, split) nor provide investor presentation content, and it is not an announcement of a report but the report itself. Therefore it fits the fallback “Regulatory Filings” category.
2025-09-30 English
Interim Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'INTERIM REPORT 2025' for Sunho Biologics, Inc. It contains detailed sections on corporate information, management discussion and analysis (MDA), and references to financial statements (e.g., 'Condensed Consolidated Statements of Profit or Loss'). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-09-26 English
APPOINTMENT OF AUDITOR
Regulatory Filings Classification · 1% confidence The document is a formal announcement by the Board of Sunho Biologics of the appointment of a new auditor to fill a casual vacancy following resignation of the prior auditor. It cites Listing Rule 13.51(4) and provides background on the selection process. It is not the audit report itself, nor an AGM or dividend notice, nor management change; it is a regulatory announcement of auditor appointment. There is no specific category for auditor appointments, so it falls under the general “Regulatory Filings” fallback.
2025-09-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.